Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT05543200
Recruiting Observational

BPH Global Registry

NCT05543200 · tracked via the Priya Life Science South Korea tracker
Sponsor
Société Internationale d'Urologie
Phase
Observational
Started
2023-03-13
Last updated
2026-08-13

Condition(s) studied

Benign Prostatic HyperplasiaLower Urinary Tract Symptoms

Study summary

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention Exclusion Criteria: * Non-symptomatic BPH * No treatment prescribed for BPH

Primary outcome measure(s)

  • International Prostate Symptom Score (IPSS) — 36 months
    Comparison of mean IPSS score change between baseline and at each follow-up during the course of the study. The scale goes from 0 (Mild) to 35 (Severe).
  • Quality of Life (QoL) — 36 months
    Comparison of mean QoL score change between baseline and at each follow-up during the course of the study. The scale is a single question which ranges from 0 to 6, with higher numbers indicating a worse quality of life.
  • Post-Void Residual (PVR) — 36 months
    Comparison of mean PVR change between baseline and at each follow-up during the course of the study.
  • Complications (including incontinence) — 36 months
    Type and Clavien grade incidences across all surgical interventions.

Trial sites (30)

FacilityCityRegionStatus
Keck Medicine of USC Los Angeles California Recruiting
Toronto Western Hospital, University Health Network Toronto Ontario Recruiting
McGill University Health Centre Montreal Quebec Recruiting
University of Montreal Hospital Center Montreal Canada Not Yet Recruiting
Hospital Dr. Juan Morey La Unión La Unión Chile Recruiting
Hospital del Trabajador Santiago Chile Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China Recruiting
University of Cyprus Nicosia Cyprus Not Yet Recruiting
The Chinese University of Hong Kong Hong Kong Hong Kong Not Yet Recruiting
Dr Baba Saheb Ambedkar Medical College and Hospital Delhi India Recruiting
Shariati Hospital Tehran Iran Recruiting
University of Basrah Basra Iraq Recruiting
Azienda Ospedaliero-Universitaria Careggi Florence Italy Recruiting
Sapienza University of Rome, Division of Urology, Ospedale Sant'Andrea Rome Italy Recruiting
Gracepark Medical Centre Meru Kenya Not Yet Recruiting
Pandya Memorial Hospital Mombasa Kenya Not Yet Recruiting
Kenyatta National Hospital Nairobi Kenya Not Yet Recruiting
American University of Beirut Beirut Lebanon Recruiting
Universiti Malaya Kuala Lumpur Malaysia Recruiting
Kati University Hospital Kati Mali Recruiting
Centro Medico Nacional Siglo XXI Mexico City Mexico Recruiting
Benue State University Teaching Hospital, Department of Surgery Makurdi Nigeria Recruiting
Ahmadu Bello University Teaching Hospital Zaria Nigeria Recruiting
Institute of Kidney Diseases Peshawar Peshawar Pakistan Recruiting
Lady Reading Hospital Peshawar Pakistan Recruiting
Hamad Medical Corporation Qatar Doha Qatar Recruiting
Seoul National University Bundang Hospital Seongnam South Korea Not Yet Recruiting
Istanbul Medipol University Istanbul Turkey (Türkiye) Recruiting
Imperial College Healthcare NHS Trust London United Kingdom Not Yet Recruiting
Southend University Hospital Southend-on-Sea United Kingdom Recruiting

Other trials for the same condition

A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers Starting soon
A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Starting soon
Study on Water Vapor Thermal Therapy Recruiting
A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05543200 on ClinicalTrials.gov ↗ ← All trials in South Korea